ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M

ReNeuron Group plc ReNeuron opens US office (7604Y)

08/12/2017 7:01am

UK Regulatory


Reneuron (LSE:RENE)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Reneuron Charts.

TIDMRENE

RNS Number : 7604Y

ReNeuron Group plc

08 December 2017

 
 8 December 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron opens US office

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA. This office will initially house the Company's US-based clinical, medical and scientific communications staff and reflects the Company's focus on clinical development activities in the US across its therapeutic programmes.

During 2018, the Company plans to have three placebo-controlled Phase IIb clinical trials running with its CTX and hRPC cell therapy candidates, in stroke disability and retinal diseases. All of these studies will be conducted in clinical trial centres across the US.

The establishment of a US office will enable the Company to more closely manage its relationships with the clinical research organisations and others involved in the conduct of these clinical trials as well as facilitating stronger ties with US-based key opinion leaders in the Company's areas of therapeutic focus.

Olav Hellebø, Chief Executive Officer of ReNeuron, said:

"We are delighted to have established operations in Boston, one of the US's most vibrant academic and commercial biotechnology hubs. The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron's clinical and commercial development strategy as our therapeutic candidates move closer to market."

ENQUIRIES:

 
ReNeuron                                                            +44 (0)20 3819 8400 
 Olav Hellebø , Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
 Buchanan                                                            +44 (0) 20 7466 5000 
 Mark Court, Sophie Wills, Stephanie Watson 
 
 Stifel Nicolaus Europe Limited                                      +44 (0) 20 7710 7600 
 Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint 
  Broker) 
 Nplus1 Singer Advisory LLP                                          +44 (0) 20 7496 3000 
 Mark Taylor (Joint Broker) 
 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

UPDOKODKKBDBNBK

(END) Dow Jones Newswires

December 08, 2017 02:01 ET (07:01 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Your Recent History

Delayed Upgrade Clock